QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Norris, B. Articles by Seale, J P. Search for Related Content PubMed PubMed Citation Articles by Norris, B. Articles by Seale, J P.

Neuroleptic Malignant Syndrome with Delayed Onset of Fever Following Risperidone Administration

Medical Student, School of Medicine, Mercer University, Macon, GA

Virginia Angeles, MD

Family Medicine Resident, Department of Family Medicine, Medical Center of Central Georgia and School of Medicine, Mercer University

Rina Eisenstein, MD

Family Medicine Resident, Department of Family Medicine, Medical Center of Central Georgia and School of Medicine, Mercer University

J Paul Seale, MD

Professor, Department of Family Medicine, Medical Center of Central Georgia and School of Medicine, Mercer University

Reprints: Dr. Seale, 3780 Eisenhower Parkway, Macon, GA 31206, fax 478/784-5496, seale.paul{at}mccg.org

OBJECTIVE: To report and discuss a case of neuroleptic malignant syndrome (NMS) with delayed onset of fever in a patient taking risperidone.

CASE SUMMARY: A 59-year-old white female presented with progressive weakness, confusion, and disorientation 10 days after restarting risperidone 2 mg/day therapy for bipolar disorder. She had taken risperidone for several years prior to this episode and had stopped it for approximately 3 weeks; risperidone was discontinued on admission. The patient's creatine kinase (CK) level was elevated (901 IU/L; reference range 39-162) on admission and increased to 1991 IU/L the following day. She was initially afebrile and had no muscular rigidity. Elevated temperature (38.1 °C) did not occur until hospital day 2. The patient was successfully treated with diazepam, bromocriptine, and dantrolene and suffered no long-term sequelae.

DISCUSSION: Other clinicians have reported atypical presentations of NMS in patients taking newer neuroleptic agents. Although this patient met diagnostic criteria for NMS, the hallmark symptoms of fever and muscle rigidity were delayed in onset. Also, the patient never remained febrile for more than 24 hours and her maximum temperature was only 38.6 °C. An objective causality assessment suggests that this case of NMS was probably related to restarting risperidone.

CONCLUSIONS: Because of the life-threatening nature of this syndrome, clinicians should consider NMS in afebrile patients presenting with diaphoresis, changes in level of consciousness, mutism, tremors, tachycardia, leukocytosis, and elevated CK levels.

Key Words: neuroleptic malignant syndrome, risperidone

Published Online, November 21, 2006. www.theannals.com, DOI 10.1345/aph.1H301

This article has been cited by other articles:

				N Jackson, J Doherty, and S Coulter Neuropsychiatric complications of commonly used palliative care drugs Postgrad. Med. J., March 1, 2008; 84(989): 121 - 126. [Abstract] [Full Text] [PDF]